跳至主要内容
临床试验/ACTRN12619000230156
ACTRN12619000230156已完成未知

Ferric Polymaltose Complex (Ferose) in Treatment of Iron Deficiency and Iron Deficiency Anemia with Pregnancy

Ahmadi Hospital, Kuwait Oil Company (KOC), Kuwait.0 个研究点目标入组 122 人开始时间: 2019年2月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
122

研究概览

简要总结

Results: The pre-treatment ferritin, and hemoglobin significantly increased, 3-months after ferric polymaltose (FPM (Ferose®)) treatment. In addition, the mean pre-treatment red-blood cells volume and red-blood cells hemoglobin significantly increased 3-months after ferric polymaltose (FPM (Ferose®)) treatment. Conclusion. The ferric polymaltose (Ferose®) is an effective therapeutic option for treatment of iron deficiency and iron deficiency anemia during pregnancy with high safety profile, and low side effects. The superior tolerability of ferric polymaltose is an important advantage because compliance to oral iron is the main obstacle toward effective treatment of iron deficiency and iron deficiency anemia.

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
20 Years 至 40 Years(—)
性别
Female

入选标准

  • Inclusion criteria include; pregnant women equal or more than 20 years old, 14-26 weeks` gestation with serum ferritin less than 15 ug/l and hemoglobin less than or equal 10 gm/dl.

排除标准

  • Exclusion criteria include; pregnant women with intolerance or hypersensitivity to oral iron and/or anemia other than iron deficiency anemia and/or received blood transfusion during current pregnancy.

研究者

发起方
Ahmadi Hospital, Kuwait Oil Company (KOC), Kuwait.

相似试验